Last reviewed · How we verify
CGB-400 Topical Gel
At a glance
| Generic name | CGB-400 Topical Gel |
|---|---|
| Also known as | CGB-400C Gel |
| Sponsor | CAGE Bio Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea (PHASE2)
- An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CGB-400 Topical Gel CI brief — competitive landscape report
- CGB-400 Topical Gel updates RSS · CI watch RSS
- CAGE Bio Inc. portfolio CI